Edwards Lifesciences, a leader in structural heart disease treatments, made its sixth consecutive appearance at the China International Import Expo (CIIE) on November 7. The company displayed its comprehensive portfolio of cutting-edge valve replacement and repair solutions, featuring the mainland debut of its PASCAL Precision transcatheter valve repair system following its recent launch in Hong Kong, China. Edwards also announced upgraded strategic partnerships with key industry players including Sinopharm Group and Shanghai Pharmaceuticals.

Wayne Markowitz, Edwards' Global Vice President for Japan and Asia-Pacific, reaffirmed the company's commitment to accelerating the introduction and clinical adoption of advanced technologies in China through CIIE's open platform, guided by its "Patient First" philosophy.

Zhong Shunhe, Senior Vice President and General Manager of Edwards Greater China, highlighted that the PASCAL Precision system's CIIE debut post-Hong Kong launch demonstrates the rapid expansion of Edwards' transcatheter valve repair innovations into the Chinese market.

The PASCAL Precision system offers a minimally invasive treatment option for high-surgical-risk patients with mitral or tricuspid regurgitation. The product is expected to receive mainland China approval next year.